Browsing Tag
Christina Coughlin
12 posts
Avacta Group (AIM: AVCT) closes oversubscribed £10m placing at 9.35% discount as AVA6103 enters clinical dosing
Avacta Group (AIM: AVCT) completes an oversubscribed £10m equity placing at 63p ahead of late-2026 AVA6103 Phase 1 data. Read the full analyst breakdown.
March 27, 2026
Avacta Therapeutics (AIM: AVCT) elevates Francis Wilson to CSO as faridoxorubicin dosing cap is removed
Avacta Therapeutics lifts AVA6000 dosing cap and appoints a new Chief Scientific Officer. Explore what this means for pre|CISION and investors.
February 11, 2026